2022
Voided Volume for Assessment of Bladder Emptying After Female Pelvic Floor Surgery: A Randomized Controlled Trial
Popiel P, Getaneh F, Yeh J, Rickey L, Bercik R, Harmanli O. Voided Volume for Assessment of Bladder Emptying After Female Pelvic Floor Surgery: A Randomized Controlled Trial. Urogynecology 2022, 28: 811-818. PMID: 36409638, DOI: 10.1097/spv.0000000000001230.Peer-Reviewed Original ResearchConceptsUrogynecologic surgeryRF groupVoided volumeSV groupUrinary tract infection rateAssessment of bladderUrinary tract infectionML of salinePelvic floor surgerySpontaneous VTVoid trialBaseline characteristicsCatheter removalPrimary outcomePrior hysterectomyTract infectionsUrinary incontinenceControlled TrialsFemale pelvic floor surgeryPatient satisfactionUrogynecologic proceduresFailure rateSurgeryInfection rateGroup SV
2016
Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic Advances In Hematology 2016, 8: 13-20. PMID: 28042455, PMCID: PMC5167078, DOI: 10.1177/2040620716676256.Peer-Reviewed Original ResearchProgression-free survivalNodular sclerosis Hodgkin lymphomaSyncytial variantOverall survivalHodgkin's lymphomaSV patientsComplete responseSV groupShorter progression-free survivalMedian overall survivalOutcomes of patientsPoor-risk groupLower CR rateInstitutional review board approvalKaplan-Meier methodSmall case seriesLog-rank testClassical HL patientsReview board approvalAdvanced diseaseInduction regimenAdult patientsClinical characteristicsHL patientsAggressive course
2015
Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.Peer-Reviewed Original ResearchNodular sclerosis Hodgkin lymphomaProgression-free survivalOutcomes of patientsAdvanced stage diseaseOverall survivalComplete responseHodgkin's lymphomaB symptomsStage diseaseSV groupAchievement of CRInferior progression-free survivalMedian progression-free survivalHodgkin/Reed-Sternberg cellsInstitutional IRB approvalMedian overall survivalStandard ABVD chemotherapyStandard salvage regimensHigh-dose therapyKaplan-Meier methodOnly independent predictorStem cell transplantStage of diseaseCompletion of treatmentNew immunomodulatory agents
1996
Does Multiple Risk Factor Reduction Explain the Reduction in Fall Rate in the Yale FICSIT Trial?
Tinetti M, McAvay G, Claus E. Does Multiple Risk Factor Reduction Explain the Reduction in Fall Rate in the Yale FICSIT Trial? American Journal Of Epidemiology 1996, 144: 389-399. PMID: 8712196, DOI: 10.1093/oxfordjournals.aje.a008940.Peer-Reviewed Original ResearchConceptsRisk factor reductionPostural blood pressure changesBlood pressure changesFall rateFactor reductionMultiple risk factor reductionCommunity-living older personsStudied risk factorsLower fall ratesGreater risk reductionFICSIT TrialsBorderline significanceIntervention groupRisk factorsFall preventionSV groupControl groupOlder personsStep lengthTertileToilet transferPressure changesChange scoresTreatment effectsRisk reduction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply